INTRODUCTION: Recent studies have reported evidence that coronavirus disease 2019 (COVID-19) has disproportionately affected patients with underlying comorbidities. Our study aims to evaluate the impact of both cardiac and noncardiac comorbidities on a high-risk population with COVID-19 infection and coronary artery disease (CAD) compared to those without CAD. METHODS: This is a retrospective study of patients who tested COVID-19 positive via reverse transcriptase-PCR (RT-PCR) assay. We compared the characteristics and outcomes of patients with and without CAD. Population demographics, comorbidities and clinical outcomes were collected and analyzed. Multivariate logistic regression analysis was used to identify factors associated with inpatient mortality. RESULTS: A final sample population of 355 patients was identified, 77 of which had a known diagnosis of coronary artery disease. Our study population had a higher proportion of females, and those with CAD were significantly older. The rates of cardiovascular risk factors including hypertension, diabetes mellitus and chronic kidney disease, as well as heart failure and chronic obstructive pulmonary disease were significantly higher in the CAD population. Lactate dehydrogenase was the only inflammatory marker significantly lower in the CAD group, while troponin and brain natriuretic peptide were significantly higher in this population. Patients with CAD also had significantly higher inpatient mortality (31% vs 20%, P = 0.046) and need for renal replacement therapy (33% vs 11%, P < 0.0001) compared to the non-CAD group. However, only age [odds ratio 1.041 (1.017-1.066), P = 0.001] was significantly associated with mortality in the overall population after adjusting for demographics and comorbidities, while the presence of CAD was not independently associated with mortality. CONCLUSION: Patients with CAD and COVID-19 have higher rates of comorbidities, inpatient mortality and need for renal replacement therapy compared to their non-CAD counterparts. However, CAD in itself was not associated with mortality after adjusting for other covariates, suggesting that other factors may play a larger role in the increased mortality and poor outcomes in these patients.
INTRODUCTION: Recent studies have reported evidence that coronavirus disease 2019 (COVID-19) has disproportionately affected patients with underlying comorbidities. Our study aims to evaluate the impact of both cardiac and noncardiac comorbidities on a high-risk population with COVID-19infection and coronary artery disease (CAD) compared to those without CAD. METHODS: This is a retrospective study of patients who tested COVID-19 positive via reverse transcriptase-PCR (RT-PCR) assay. We compared the characteristics and outcomes of patients with and without CAD. Population demographics, comorbidities and clinical outcomes were collected and analyzed. Multivariate logistic regression analysis was used to identify factors associated with inpatient mortality. RESULTS: A final sample population of 355 patients was identified, 77 of which had a known diagnosis of coronary artery disease. Our study population had a higher proportion of females, and those with CAD were significantly older. The rates of cardiovascular risk factors including hypertension, diabetes mellitus and chronic kidney disease, as well as heart failure and chronic obstructive pulmonary disease were significantly higher in the CAD population. Lactate dehydrogenase was the only inflammatory marker significantly lower in the CAD group, while troponin and brain natriuretic peptide were significantly higher in this population. Patients with CAD also had significantly higher inpatient mortality (31% vs 20%, P = 0.046) and need for renal replacement therapy (33% vs 11%, P < 0.0001) compared to the non-CAD group. However, only age [odds ratio 1.041 (1.017-1.066), P = 0.001] was significantly associated with mortality in the overall population after adjusting for demographics and comorbidities, while the presence of CAD was not independently associated with mortality. CONCLUSION:Patients with CAD and COVID-19 have higher rates of comorbidities, inpatient mortality and need for renal replacement therapy compared to their non-CAD counterparts. However, CAD in itself was not associated with mortality after adjusting for other covariates, suggesting that other factors may play a larger role in the increased mortality and poor outcomes in these patients.
Authors: Alessandra Scoccia; Guglielmo Gallone; Alberto Cereda; Anna Palmisano; Davide Vignale; Riccardo Leone; Valeria Nicoletti; Chiara Gnasso; Alberto Monello; Arif Khokhar; Alessandro Sticchi; Andrea Biagi; Carlo Tacchetti; Gianluca Campo; Claudio Rapezzi; Francesco Ponticelli; Gian Battista Danzi; Marco Loffi; Gianluca Pontone; Daniele Andreini; Gianni Casella; Gianmarco Iannopollo; Davide Ippolito; Giacomo Bellani; Gianluigi Patelli; Francesca Besana; Claudia Costa; Luigi Vignali; Giorgio Benatti; Mario Iannaccone; Paolo Giacomo Vaudano; Alberto Pacielli; Caterina Chiara De Carlini; Stefano Maggiolini; Pietro Andrea Bonaffini; Michele Senni; Elisa Scarnecchia; Fabio Anastasio; Antonio Colombo; Roberto Ferrari; Antonio Esposito; Francesco Giannini; Marco Toselli Journal: Atherosclerosis Date: 2021-04-07 Impact factor: 5.162
Authors: Mateusz Sokolski; Konrad Reszka; Tomasz Suchocki; Barbara Adamik; Adrian Doroszko; Jarosław Drobnik; Joanna Gorka-Dynysiewicz; Maria Jedrzejczyk; Krzysztof Kaliszewski; Katarzyna Kilis-Pstrusinska; Bogusława Konopska; Agnieszka Kopec; Anna Larysz; Weronika Lis; Agnieszka Matera-Witkiewicz; Lilla Pawlik-Sobecka; Marta Rosiek-Biegus; Justyna M Sokolska; Janusz Sokolowski; Anna Zapolska-Tomasiewicz; Marcin Protasiewicz; Katarzyna Madziarska; Ewa A Jankowska Journal: J Clin Med Date: 2022-01-03 Impact factor: 4.241
Authors: Josh McGovern; Yassir Al-Azzawi; Olivia Kemp; Peter Moffitt; Conor Richards; Ross D Dolan; Barry J Laird; Donald C McMillan; Donogh Maguire Journal: J Transl Med Date: 2022-02-21 Impact factor: 5.531